10 Market Winners With Stunning Gains

Page 9 of 9

1. ImmunityBio Inc. (NASDAQ:IBRX)

ImmunityBio soared to a new 52-week high on Wednesday, as investors gobbled up shares over an aggressive international expansion for its therapy, Anktiva.

At intra-day trading, the stock climbed to its highest price of $8.68 before trimming gains to end the day just up by 41.86 percent at $8.54 apiece.

In a statement, Immunitybio Inc. (NASDAQ:IBRX) said that the European Commission has issued its conditional marketing authorization for the sale of  Anktiva + BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following a positive opinion from the European Medicines Agency on December 11.

The CMA is an early authorization that aims to accelerate the approval of life-saving medicines and vaccines in Europe.

Once fully approved, Immunitybio Inc. (NASDAQ:IBRX) would then be allowed to sell Anktiva in 33 countries in Europe.

“With Anktiva now authorized in 33 countries from the United States and the United Kingdom to the European Union and Saudi Arabia, we have built the broadest global access platform for an immunotherapy in this indication. With more than 80 percent of treated patients preserving their bladder through three years of follow-up, Anktiva represents a meaningful advance designed to strengthen the immune response and extend the durability of BCG,” said Immunitybio Inc. (NASDAQ:IBRX) Executive Chairman Patrick Soon-Shiong.

While we acknowledge the potential of IBRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IBRX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.

Page 9 of 9